Potrelease TR Tablet Mechanism of Action

Pharmacology: Pharmacodynamics: Mode or Mechanisms of Action: Potassium is the predomination cation of (150 mEq per liter) within cells. Intracellular sodium content is relatively low. In extracellular fluid, sodium predominates and the potassium content is low (4 to 5 mEq per liter). A membrane-bound enzyme, sodium-potassium-activated adenosine triphosphatase (Na+ -K+ ATPase), actively transports or pumps sodium out of and potassium into cells in order to maintain these concentration gradients. The gradients are necessary for the conduction of nerve impulses in such specialized tissues as the heart, brain, and skeletal muscle, and to maintain normal renal function and acid-base balance. High intracellular potassium concentrations are necessary for numerous cellular metabolic processes.
Pharmacokinetics: Onset and Duration: Peak elevation of serum potassium levels following SR preparations is highly delayed (2hours) compared to liquid form (1hour).
Effect on serum potassium is generally confined to the first 3 hours after dosing.
Plasma Levels: (May vary depending on laboratory) 3.5 - 5 mEq/L (adult and child); 5 - 7.5 mEq/L (newborn); total body stores are approximately 50 mEq/kg or 3500 mEq. As a general rule, a decrease of 1 mEq/L in serum potassium reflects a 10 - 20% total body deficit; however, there is considerable variation; signs of hypokalaemia appear below 2.5 mEq/L; Levels above 7 mEq/L are dangerous. Clinical signs of hyperkalaemia are not reliable indicators of serum levels. Alkalosis decreases levels and acidosis increases levels.
Fate: When initially administered the rates of absorption and excretion are more rapid with the liquid than the SR forms; however, bioavailability is the same when administered long-term (78-90%). Approximately 10 mEq/day are eliminated in the feces; 7.5mEq/L in sweat and 60 - 90 mEq/day in urine.